The prognostic model reported by Guru Sonpavde et al. combined genomic and clinical factors to predict the response to anti-PD-1/PD-L1 therapy among 62 patients with advanced urothelial carcinoma (11), and the results also need further validation due to the limited sample size. This evidence concerns the gene PDCD1 and urothelial carcinoma.